Evidence map›Paper›PMID 36148887›Full record

Observational studyPerfusion2023

Bleeding and thrombotic complications and their impact on mortality in patients supported with left ventricular assist device for cardiogenic shock.

Ingrid Bekono-Nessah, Alex Rosenburg, Christopher T Bowles, Fernando Riesgo-Gil, Ulrich Stock, Richard R Szydlo, Mike Laffan, Deepa J Arachchillage

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Perfusion, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ingrid Bekono-NessahCentre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
Alex RosenburgDepartment of critical care, Royal Brompton & Harefield Hospitals, Part of Guy's & St Thomas' NHS Foundation Trust, London, UK.
Christopher T BowlesDepartment of critical care, Royal Brompton & Harefield Hospitals, Part of Guy's & St Thomas' NHS Foundation Trust, London, UK.
Fernando Riesgo-GilDepartment of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield Hospitals, Part of Guy's & St Thomas' NHS Foundation Trust, London, UK.
Ulrich StockDepartment of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton & Harefield Hospitals, Part of Guy's & St Thomas' NHS Foundation Trust, London, UK.
Richard R SzydloCentre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
Mike LaffanCentre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
Deepa J ArachchillageCentre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.ORCID 0000-0001-5993-4850
Guy's and St Thomas' NHS Foundation Trust · GBImperial College London · GBHarefield Hospital · GB

Funding

Medical Research Council MR/V037633/1
6 · The paper itself

Abstract

introductionThrombosis and bleeding are major complications in patients supported with left ventricular assist devices (LVADs). We aimed to assess the incidence of bleeding and thrombosis in patients supported with a HeartWare left ventricular assist device (HVAD), their predictive factors and their impact on mortality.

methodsA single centre retrospective observational study of patients supported with HVAD over 5 years from January 2015 to October 2020.

resultsA total 139 patients (median age 52.5, 72.1% male) were included for analysis. The probability of 1-year survival was 73.1%. Advanced age (>60 years) and EuroSCORE II score (>20%) were independently associated with reduced survival. Major bleeding and thrombosis occurred in 46.8% and 35.3% respectively. Secondary mechanical circulatory support (MCS) increased likelihood of experiencing major bleeding (HR: 2.76, 95%1.65-4.62,

conclusionsMajor bleeding and thrombosis significantly increase the 1-year mortality. Optimal perioperative haemostasis and anticoagulation remains crucial in patients supported with HVAD.

Indexed as

Heart-Assist DevicesHeart FailureThrombosisFemaleHemorrhageHumansMaleMiddle AgedRetrospective StudiesShock, CardiogenicTreatment Outcomeanaemiableedingleft ventricular assist devicemortalitythrombosis

Identifiers

PMID36148887
PMCPMC11057213
OpenAlexW4296806004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.